Literature DB >> 9510198

Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene.

J E Fenyk-Melody1, A E Garrison, S R Brunnert, J R Weidner, F Shen, B A Shelton, J S Mudgett.   

Abstract

Nitric oxide is believed to be a prominent mediator of inflammation based in part on the correlative expression of the inducible nitric oxide synthase (iNOS) gene in various pathologies. The resulting high output of the highly reactive molecule nitric oxide is then believed to play an important role in the evolving inflammatory response. Studies have shown that iNOS and nitric oxide are present in the tissues of patients with multiple sclerosis (MS). In rodent models of MS, experimental autoimmune encephalomyelitis (EAE), it has been shown that nonspecific NOS inhibitors partially ameliorate the disease. To determine the importance of iNOS in this model of MS, we induced EAE in mice containing a disrupted iNOS (NOS2) gene. Surprisingly, by day 24, the NOS2 knockout mice had a greater incidence of EAE than wild-type control mice (75 vs 12%), and had a higher average severity score (2.42 vs 0.44). These differences appear to result largely from the failure of the disease to remit in NOS2 KO mice. Wild-type mice have a profound ability to reverse EAE (82%) compared with the knockout mice (19%). This result implies that iNOS may in some instances play a protective role in autoimmune-mediated tissue destruction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510198

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses.

Authors:  Daniela Giordano; Chang Li; Mehul S Suthar; Kevin E Draves; Daphne Y Ma; Michael Gale; Edward A Clark
Journal:  J Leukoc Biol       Date:  2010-12-22       Impact factor: 4.962

2.  In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes.

Authors:  S Y Yao; A Ljunggren-Rose; N Chandramohan; W O Whetsell; S Sriram
Journal:  J Neuroimmunol       Date:  2010-08-19       Impact factor: 3.478

3.  Nitric oxide inhibits exocytosis of cytolytic granules from lymphokine-activated killer cells.

Authors:  Marcella Ferlito; Kaikobad Irani; Nauder Faraday; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-20       Impact factor: 11.205

4.  RNA-Binding Protein HuR Promotes Th17 Cell Differentiation and Can Be Targeted to Reduce Autoimmune Neuroinflammation.

Authors:  Jing Chen; Jennifer L Martindale; Kotb Abdelmohsen; Gaurav Kumar; Paolo M Fortina; Myriam Gorospe; Abdolmohamad Rostami; Shiguang Yu
Journal:  J Immunol       Date:  2020-03-13       Impact factor: 5.422

5.  9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes.

Authors:  Jihong Xu; Paul D Drew
Journal:  J Neuroimmunol       Date:  2005-11-21       Impact factor: 3.478

6.  Role of inducible nitric oxide synthase in the regulation of neutrophil migration in zymosan-induced inflammation.

Authors:  M N Ajuebor; L Virág; R J Flower; M Perretti; C Szabó
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

7.  Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.

Authors:  Susanta Mondal; Saurav Brahmachari; Kalipada Pahan
Journal:  J Clin Cell Immunol       Date:  2012-07-16

8.  Endothelial NOS-deficient mice reveal dual roles for nitric oxide during experimental autoimmune encephalomyelitis.

Authors:  Muzhou Wu; Stella E Tsirka
Journal:  Glia       Date:  2009-08-15       Impact factor: 7.452

9.  Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide.

Authors:  Saurav Brahmachari; Kalipada Pahan
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

Review 10.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.

Authors:  Guy C Brown; Anna Bal-Price
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.